One dose might be enough to last a lifetime
For generations, the management of high cholesterol has meant a lifetime of medication — a quiet, relentless negotiation between patient and pill. Now, a gene-editing treatment called VERVE-102, developed by Verve Therapeutics and advanced by Eli Lilly, has shown in early trials that a single injection may achieve what daily or biweekly drugs accomplish, but perhaps only once. The results invite a deeper question: what becomes possible when medicine stops managing the symptoms of our biology and begins rewriting its instructions.
- A single dose of VERVE-102 slashed LDL cholesterol by up to 62% and its target protein PCSK9 by 88% — numbers that rival the best existing drugs on the market.
- The critical difference is durability: where current PCSK9 inhibitors demand injections every two to four weeks for life, the gene editor's effects persisted after just one dose.
- High cholesterol afflicts roughly one in five American adults and is a leading driver of heart attacks and strokes, making medication adherence a chronic, life-or-death problem the current system struggles to solve.
- Eli Lilly is advancing VERVE-102 to Phase 2 trials, where larger patient groups and longer follow-up periods will test both efficacy and the long-term safety of human gene editing.
- The field is watching closely — if the results hold, this could mark the opening of an entirely new class of one-time treatments for genetic cardiovascular risk factors.
Eli Lilly has announced early trial results for VERVE-102, a gene-editing therapy developed by Verve Therapeutics that targets the root of high cholesterol rather than its downstream effects. In the study, a single injection reduced PCSK9 — a protein that governs how much LDL cholesterol the body clears from the bloodstream — by up to 88 percent, and lowered LDL itself by as much as 62 percent.
Those figures are comparable to existing PCSK9 inhibitor drugs, but the implications are different in kind. Current medications require injections every two to four weeks indefinitely, and many patients — particularly those at highest cardiovascular risk — struggle to maintain that regimen. VERVE-102 works by editing the gene that produces PCSK9, making a stable, lasting change rather than repeatedly blocking the protein's action. The effects persisted throughout the study, suggesting one dose may be sufficient.
High cholesterol remains one of the most prevalent risk factors for heart disease in the United States, affecting roughly one in five adults. The prospect of a one-time treatment could fundamentally change the calculus for patients and clinicians alike, removing the adherence burden that undermines so many long-term therapies.
Lilly's move to Phase 2 trials reflects confidence in the early data, though the road ahead is long. Regulators will require extensive safety data before any gene-editing therapy reaches widespread use, and the coming years of follow-up will be decisive. For now, the results represent something the field has been anticipating: a credible step toward treating not just the symptoms of cardiovascular disease, but the biological machinery behind it.
Eli Lilly announced results from early trials of a gene-editing treatment that could fundamentally change how doctors manage high cholesterol. The drug, called VERVE-102, was developed by Verve Therapeutics and works by editing a single gene responsible for cholesterol production in the body. In the initial study, a single injection reduced the target protein PCSK9 by as much as 88 percent and lowered LDL cholesterol—the kind that clogs arteries—by up to 62 percent.
Those numbers matter because they match what existing cholesterol drugs achieve, but with a crucial difference: those existing medications, called PCSK9 inhibitors, require patients to take injections every two to four weeks for the rest of their lives. VERVE-102 appears to work differently. The effects persisted in the study, suggesting that one dose might be enough. If that holds up in larger trials, it would represent a significant shift in how we treat one of the most common risk factors for heart disease.
High cholesterol affects roughly one in five American adults and is a major driver of heart attacks and strokes. Current treatments work well but demand ongoing commitment—patients must remember to get their injections or take their pills regularly, and many don't. A treatment that works once and lasts could change the calculus entirely, particularly for people at high risk of cardiovascular disease who struggle with medication adherence.
The gene-editing approach targets PCSK9, a protein that regulates how much LDL cholesterol the body removes from the bloodstream. By editing the gene that produces this protein, the treatment essentially turns down the volume on cholesterol production at its source. This is different from existing drugs, which block the protein's action without changing the underlying genetics. The durability of the effect—the fact that it persisted after a single dose—suggests the edit is stable and lasting.
Lilly's decision to move forward to Phase 2 trials signals confidence in the approach. Phase 2 studies will involve more patients and longer follow-up periods, testing not just whether the treatment works but whether it's safe over time. Gene editing in humans is still relatively new territory, and regulators will want extensive data before approving any therapy for widespread use. The company is betting that the early results are solid enough to justify the investment in larger, more rigorous studies.
What makes this moment significant is not just the numbers but what they represent: a shift from managing disease symptoms to potentially altering the biological machinery that causes disease in the first place. If VERVE-102 proves safe and effective in Phase 2, it could open the door to a new class of treatments for cholesterol and other genetic risk factors. The real test will come in the coming years, as researchers follow patients longer and test the treatment in broader populations. For now, Lilly has given the field something to watch.
Citações Notáveis
The durable effects support its potential as a one-time treatment for hypercholesterolemia— Eli Lilly investor statement
A Conversa do Hearth Outra perspectiva sobre a história
Why does a one-time treatment matter so much more than a drug you take every few weeks?
Because most people don't take their medications consistently. A pill or injection you have to remember every few days—or every few weeks—gets missed. Life gets in the way. With a one-time edit, there's no forgetting, no lapsing, no reason to stop.
But this is gene editing. Doesn't that scare people?
It should prompt careful thought, yes. But the alternative is a lifetime of injections for something that could be fixed once. The fear is real, but so is the burden of chronic disease management. People will weigh them differently.
What could go wrong in Phase 2?
Safety signals. Off-target effects. The edit might work in a small group but cause problems in a larger, more diverse population. Or the durability might not hold as long as early data suggests. Gene editing is precise, but it's not perfect.
If this works, does it change medicine?
It changes the conversation about what's possible. Right now we manage risk factors. This would be preventing them at the genetic level. That's a different paradigm entirely.
Who benefits most?
People at highest risk of heart disease who struggle with medication adherence. But also anyone who'd rather have one procedure than a lifetime of treatment. That's most people.